Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with high-risk or lymph node positive prostate cancer who are receiving radiation therapy, and if it will result in fewer gastrointestinal and genitourinary side effects. Proton beam therapy is a new type of radiotherapy that directs multiple beams of protons (positively charged subatomic particles) at the tumor target, where they deposit the bulk of their energy with essentially no residual radiation beyond the tumor. By r

Trial Details

NCT ID
NCT04725903
Phase
NA
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • High-Dose Rate Brachytherapy
  • Proton Beam Radiation Therapy
  • Quality-of-Life Assessment
  • Survey Administration
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Pathologically confirmed high-risk prostate cancer fulfilling any one of the following criteria:
  • Gleason grade 8 or higher
  • cT3b (seminal vesicle involvement) or cT4
  • Prostate specific antigen \[PSA\] \> 20 (or PSA \>10 if on finasteride)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →